Articles found by an AI-assisted PubMed search that may be missing from CancerImmunoDB, shared so that curators and users can see what is being considered.
Why this exists: the database holds only about 10 articles a year for 2021–2024, and a plain PubMed search cannot judge whether a paper fits the scope.
| Year | Screened | Likely relevant |
|---|---|---|
| 2026 | 99 | 61 |
| 2025 | 100 | 81 |
| 2024 | 98 | 72 |
| 2023 | 92 | 45 |
| 2022 | 100 | 52 |
| 2021 | 85 | 49 |
360 articles shown. “In the database” counts the entries the database already has for each drug the AI named (cell line / animal / patient).
| PMID | Year | Article | Drugs | Study type | Cancer type | In the database | Curator status |
|---|---|---|---|---|---|---|---|
| 36708811 | 2023 | Identification of a tumour immune barrier in the HCC microenvironment that determines the efficacy of immunotherapy. Journal of hepatology Likely relevant The study experimentally tests anti-PD-1 treatment and SPP1 blockade in mouse models of liver cancer and HCC patients, and measures immune cell infiltration. | anti-PD-1; SPP1 blockade | Mixed | hepatocellular carcinoma | anti-PD-1 14/36/0; SPP1 blockade 0/0/0 | Awaiting curator check |
| 36795805 | 2023 | CD5 expression by dendritic cells directs T cell immunity and sustains immunotherapy responses. Science (New York, N.Y.) Likely relevant The study investigates the role of CD5+ dendritic cells and their interaction with immune checkpoint blockade in vivo, measuring T cell priming and tumor elimination. | immune checkpoint blockade | Animal | melanoma | immune checkpoint blockade 0/1/0 | Awaiting curator check |
| 36835382 | 2023 | Identification of CBPA as a New Inhibitor of PD-1/PD-L1 Interaction. International journal of molecular sciences Likely relevant Evaluates the PD-1/PD-L1 small-molecule inhibitor CBPA in mouse tumor models, measuring cytokine secretion and T cell infiltration. | CBPA | Animal | colon adenocarcinoma and melanoma | CBPA 0/0/0 | Awaiting curator check |
| 36842157 | 2023 | PD-1/PD-L1 blockade inhibits epithelial-mesenchymal transition and improves chemotherapeutic response in breast cancer. Medical oncology (Northwood, London, England) Likely relevant Experimentally tests PD-L1 inhibitors and chemotherapy in vitro and in vivo, measuring T cell-mediated cell killing. | PD-L1 inhibitor; chemotherapy | Mixed | breast cancer | PD-L1 inhibitor 0/0/0; chemotherapy 2/0/3 | Awaiting curator check |
| 36853831 | 2023 | Decitabine priming increases anti-PD-1 antitumor efficacy by promoting CD8+ progenitor exhausted T cell expansion in tumor models. The Journal of clinical investigation Likely relevant The study tests decitabine and anti-PD-1 in vitro and in tumor models, reporting detailed cellular and molecular immune readouts such as T cell expansion, proliferation, and cytolytic activity. | decitabine; anti-PD-1 | Mixed | tumor models | decitabine 100/12/2; anti-PD-1 14/36/0 | Awaiting curator check |
| 36914658 | 2023 | Polymerase θ inhibition activates the cGAS-STING pathway and cooperates with immune checkpoint blockade in models of BRCA-deficient cancer. Nature communications Likely relevant Characterizes the effects of polymerase theta inhibition and anti-PD-1 in immunocompetent breast and pancreatic cancer models, measuring immune responses and cGAS/STING activation. | polymerase theta inhibitors; anti-PD-1 | Animal | triple-negative breast cancer and pancreatic ductal adenocarcinoma | polymerase theta inhibitors 0/0/0; anti-PD-1 14/36/0 | Awaiting curator check |
| 36963400 | 2023 | Neutralizing IL-8 potentiates immune checkpoint blockade efficacy for glioma. Cancer cell Likely relevant The study tests antibody-mediated IL-8 blockade and CXCR1/2 inhibitors in mouse models and measures effects on immunosuppressive cell infiltration and anti-PD-1 efficacy. | anti-PD-1; IL-8 blocking antibody; CXCR1/2 inhibitor | Animal | glioma | anti-PD-1 14/36/0; IL-8 blocking antibody 0/0/0; CXCR1/2 inhibitor 0/0/0 | Awaiting curator check |
| 37019619 | 2023 | Targeting PPAR-gamma counteracts tumour adaptation to immune-checkpoint blockade in hepatocellular carcinoma. Gut Likely relevant The study tests anti-PD-L1 and a PPARgamma antagonist in animal models and patient samples, measuring MDSC accumulation and CD8+ T cell conversion. | anti-PD-L1; pembrolizumab; selective PPARgamma antagonist | Mixed | hepatocellular carcinoma | anti-PD-L1 0/15/0; pembrolizumab 0/0/16; selective PPARgamma antagonist 0/0/0 | Awaiting curator check |
| 37026630 | 2023 | Ferroptosis Signature Shapes the Immune Profiles to Enhance the Response to Immune Checkpoint Inhibitors in Head and Neck Cancer. Advanced science (Weinheim, Baden-Wurttemberg, Germany) Likely relevant The study experimentally tests ferroptosis inducers and anti-PD-L1 antibodies in a murine HNSCC model and measures immune-related readouts such as PD-L1 expression and active immune cell profiles. | anti-PD-L1 antibody; ferroptosis inducer | Animal | Head and Neck Squamous Cell Carcinoma | anti-PD-L1 antibody 0/1/0; ferroptosis inducer 0/0/0 | Awaiting curator check |
| 37027467 | 2023 | Small-molecule PIK-93 modulates the tumor microenvironment to improve immune checkpoint blockade response. Science advances Likely relevant The study tests the small molecule PIK-93 in combination with anti-PD-L1 antibodies in vitro and in vivo, and measures effects on macrophage PD-L1, cytotoxicity, T cell activation, and TIL recruitment. | PIK-93; anti-PD-L1 antibody | Mixed | non-small cell lung cancer | PIK-93 0/0/0; anti-PD-L1 antibody 0/1/0 | Awaiting curator check |
| 37028428 | 2023 | Dietary tryptophan metabolite released by intratumoral Lactobacillus reuteri facilitates immune checkpoint inhibitor treatment. Cell Likely relevant The study experimentally tests immune checkpoint inhibitors in combination with probiotics/metabolites in a preclinical melanoma model and measures CD8+ T cell responses. | immune checkpoint inhibitor | Animal | melanoma | immune checkpoint inhibitor 0/0/0 | Awaiting curator check |
| 37080489 | 2023 | Sustained release hydrogel for durable locoregional chemoimmunotherapy for BRAF-mutated melanoma. Journal of controlled release : official journal of the Controlled Release Society Likely relevant The study tests a BRAF inhibitor (vemurafenib) and anti-PD-1 antibody in murine melanoma models, reporting local immunomodulation. | vemurafenib; antagonistic programmed cell death protein 1 antibody (aPD-1) | Animal | melanoma | vemurafenib 52/2/7; antagonistic programmed cell death protein 1 antibody (aPD-1) 0/0/0 | Awaiting curator check |
| 37106265 | 2023 | An HPK1 inhibitor enhanced the tumour response to anti-PD-1 immunotherapy in non-Hodgkin's lymphoma. Clinical and experimental medicine Likely relevant Investigates the effects of an HPK1 inhibitor combined with anti-PD-1 immunotherapy on T-cell cytotoxicity and immune marker expression in cell lines and xenograft models. | HPK1 inhibitor; anti-PD-1 | Mixed | non-Hodgkin's lymphoma | HPK1 inhibitor 0/0/0; anti-PD-1 14/36/0 | Awaiting curator check |
| 37138075 | 2023 | Targeting PD-L2-RGMb overcomes microbiome-related immunotherapy resistance. Nature Likely relevant The study experimentally tests PD-L2-RGMb pathway blocking antibodies combined with anti-PD-1/anti-PD-L1 in mice and measures anti-tumor immune responses. | anti-PD-1; anti-PD-L1; anti-PD-L2-RGMb pathway blocking antibodies | Animal | cancer (multiple mouse tumour models) | anti-PD-1 14/36/0; anti-PD-L1 0/15/0; anti-PD-L2-RGMb pathway blocking antibodies 0/0/0 | Awaiting curator check |
| 37192546 | 2023 | Induction of Tumor Ferroptosis-Dependent Immunity via an Injectable Attractive Pickering Emulsion Gel. Advanced materials (Deerfield Beach, Fla.) Likely relevant The study experimentally tests RSL-3 and PD-1 antibody in tumour-bearing animals and reports measured effects on immune cell accumulation and antitumor immune response. | (1S, 3R)-RSL-3; programmed death-1 (PD-1) antibody | Animal | hepatocellular carcinoma and pancreatic cancer | (1S, 3R)-RSL-3 0/0/0; programmed death-1 (PD-1) antibody 0/0/0 | Awaiting curator check |
| 37193754 | 2023 | Bis(benzonitrile) dichloroplatinum (II) interrupts PD-1/PD-L1 interaction by binding to PD-1. Acta pharmacologica Sinica Likely relevant Tests platinum compounds in immunocompetent mice with colorectal cancer xenografts and measures tumor-infiltrating T cells. | bis(benzonitrile) dichloroplatinum (II); cisplatin | Animal | colorectal cancer | bis(benzonitrile) dichloroplatinum (II) 0/0/0; cisplatin 18/3/11 | Awaiting curator check |
| 37247886 | 2023 | Differential Effects of Anti-PD-1/PD-L1 Checkpoint Inhibitors on Adhesion Molecules and Cytokine Secretion by THP-1 Monocytes. Anticancer research Likely relevant Experimentally tests anti-PD-1/PD-L1 antibodies on the THP-1 cell line and measures apoptosis, adhesion molecule expression, and cytokine release. | Nivolumab; Pembrolizumab; Atezolizumab; Durvalumab | Cell line | monocytic leukemia | Nivolumab 1/2/4; Pembrolizumab 0/0/16; Atezolizumab 0/0/4; Durvalumab 0/0/2 | Awaiting curator check |
| 37311042 | 2023 | PTEN Loss Confers Resistance to Anti-PD-1 Therapy in Non-Small Cell Lung Cancer by Increasing Tumor Infiltration of Regulatory T Cells. Cancer research Likely relevant Tests anti-PD-1, TLR agonists, and anti-TGFβ antibody in a Pten-null LUSC mouse model and measures immune readouts like Treg infiltration and PD-L1/PD-L2 levels. | anti-programmed cell death protein 1 (anti-PD-1); TLR agonists; anti-TGFβ antibody | Animal | Non-Small Cell Lung Cancer | anti-programmed cell death protein 1 (anti-PD-1) 0/0/0; TLR agonists 0/0/0; anti-TGFβ antibody 0/0/0 | Awaiting curator check |
| 37344596 | 2023 | Y chromosome loss in cancer drives growth by evasion of adaptive immunity. Nature Likely relevant The study tests the response to anti-PD-1 immune checkpoint blockade therapy in mice and patients with bladder cancer with loss of the Y chromosome, measuring CD8+ T cell exhaustion. | anti-PD-1 | Mixed | bladder cancer | anti-PD-1 14/36/0 | Awaiting curator check |
| 37357254 | 2023 | TRIM28 promotes the escape of gastric cancer cells from immune surveillance by increasing PD-L1 abundance. Signal transduction and targeted therapy Likely relevant Evaluates PD-L1 and TBK1 inhibitors in mice, measuring changes in T cell activation and tumor progression. | PD-L1 inhibitor; TBK1 inhibitor; CTLA4 | Animal | gastric cancer | PD-L1 inhibitor 0/0/0; TBK1 inhibitor 0/0/0; CTLA4 0/0/0 | Awaiting curator check |
| 37429863 | 2023 | ARIH1 activates STING-mediated T-cell activation and sensitizes tumors to immune checkpoint blockade. Nature communications Likely relevant The study experimentally tests cisplatin and ACY738 in mouse tumor models and measures their effects on cytotoxic T cell infiltration and STING signaling. | cisplatin; PD-L1 blockade; ACY738 | Animal | tumor model | cisplatin 18/3/11; PD-L1 blockade 0/4/0; ACY738 0/0/0 | Awaiting curator check |
| 37430270 | 2023 | Single-cell RNA sequencing reveals enhanced antitumor immunity after combined application of PD-1 inhibitor and Shenmai injection in non-small cell lung cancer. Cell communication and signaling : CCS Likely relevant Evaluates the combination of PD-1 inhibitor and Shenmai injection in mouse models and in vitro, reporting comprehensive immune readouts on NK cells and T cells. | PD-1 inhibitor; Shenmai injection | Mixed | Non-Small Cell Lung Cancer | PD-1 inhibitor 0/0/0; Shenmai injection 0/0/0 | Awaiting curator check |
| 37474523 | 2023 | Tumor-derived GDF-15 blocks LFA-1 dependent T cell recruitment and suppresses responses to anti-PD-1 treatment. Nature communications Likely relevant The study tests anti-GDF-15 neutralization and PD-1 blockade in murine tumor models and patient samples, measuring T cell trafficking and extravasation. | anti-PD-1; anti-GDF-15 antibody | Mixed | melanoma | anti-PD-1 14/36/0; anti-GDF-15 antibody 0/0/0 | Awaiting curator check |
| 37515321 | 2023 | Targeting leucine-rich repeat serine/threonine-protein kinase 2 sensitizes pancreatic ductal adenocarcinoma to anti-PD-L1 immunotherapy. Molecular therapy : the journal of the American Society of Gene Therapy Likely relevant The study experimentally tests LRRK2 inhibitors, anti-PD-L1, and adenosylcobalamin in cell lines and mice, measuring effects on CD8+ T cells and immune responses. | anti-PD-L1; adenosylcobalamin | Mixed | pancreatic ductal adenocarcinoma | anti-PD-L1 0/15/0; adenosylcobalamin 0/0/0 | Awaiting curator check |
| 37543621 | 2023 | Combined PD-L1/TGFβ blockade allows expansion and differentiation of stem cell-like CD8 T cells in immune excluded tumors. Nature communications Likely relevant Tests combined TGFbeta and PD-L1 blockade in a mouse tumor model, measuring CD8 T cell compartments and IFNgamma signaling. | anti-PD-L1; anti-TGFbeta | Animal | breast cancer | anti-PD-L1 0/15/0; anti-TGFbeta 0/0/0 | Awaiting curator check |